Bauer & Cie. v. O'Donnell

Last updated
Bauer & Cie. v. O'Donnell
Seal of the United States Supreme Court.svg
Argued April 10, 1913
Decided May 26, 1913
Full case nameBauer & Cie. and the Bauer Chemical Company v. James O'Donnell
Citations229 U.S. 1 ( more )
33 S. Ct. 616; 57 L. Ed. 1041; 1913 U.S. LEXIS 2417
Case history
SubsequentCertificate from the Court of appeals of the District of Columbia.
Court membership
Chief Justice
Edward D. White
Associate Justices
Joseph McKenna  · Oliver W. Holmes Jr.
William R. Day  · Horace H. Lurton
Charles E. Hughes  · Willis Van Devanter
Joseph R. Lamar  · Mahlon Pitney
Case opinions
MajorityDay, joined by White, Hughes, Lamar, Pitney
DissentHolmes, joined by McKenna, Lurton, Van Devanter

Bauer & Cie. v. O'Donnell, 229 U.S. 1 (1913), was a 1913 United States Supreme Court decision involving whether a purchaser of a patented product bearing a price-fixing notice incurs guilt of patent infringement by reselling the product at a price lower than that which the notice commands. A divided Court (5–4) held that it was not.

Contents

Bauer & Cie, a German company, was the assignee of U.S. Patent No. 601,995, covering Sanatogen, a water-soluble drug product (patent medicine), advertised as the "King of Tonics" and a strength-giving "concentrated scientific food." [1] Bauer sold the patented product in the United States through its exclusive sales agent, Hehmeyer, under a license agreement. [2] Sanatogen was sold with this notice on each bag:

Notice to the Retailer.

This size package of Sanatogen is licensed by us for sale and use at a price not less than one dollar ($1.00). Any sale in violation of this condition, or use when so sold, will constitute an infringement of our patent No. 601,995, under which Sanatogen is manufactured, and all persons so selling or using packages or contents will be liable to injunction and damages.

A purchase is an acceptance of this condition. All rights revert to the undersigned in the event of violation. [3]

O'Donnell, a retail druggist in Washington, DC, purchased Sanatogen at wholesale and resold the Sanatogen for less than $1. He persisted in doing this and was cut off, but he managed to continue to purchase the product from jobbers in DC "and avers that he will continue such sales." This led to the present patent infringement suit. The Court of Appeals of the District of Columbia certified the case to the Supreme Court with this question:

Did the Acts of the appellee [O'Donnell] in retailing at less than the price fixed in said notice on original packages of Sanatogen purchased of jobbers, as aforesaid, constitute infringement of appellants' patent?

Ruling of Supreme Court

Justice Day delivered the majority opinion. William Rufus Day cph.3b31004.jpg
Justice Day delivered the majority opinion.

Justice William R. Day delivered the majority opinion, joined by Justices White, Hughes, Lamar, Pitney. Justices McKenna, Holmes, Lurton, and Van Devanter dissented without opinion.

The Court restated the question before it as:

The question therefore now before this Court for judicial determination, is: may a patentee, by notice, limit the price at which future retail sales of the patented article may be made, such article being in the hands of a retailer by purchase from a jobber who has paid to the agent of the patentee the full price asked for the article sold? [4]

The patentee argued that the purpose of the restrictive notice was "to prevent ruinous competition by the cutting of prices in sales of the patented article." Day responded, however, that absent a patent the Court had held resale price fixing unlawful in Dr. Miles Medical Co. v. John D. Park & Sons Co. And Congress could, if it had wanted to, have conferred on patentees the right to impose such restrictions. He then asked:

Has it done so? The question has not been determined in any previous case in this Court, so far as we are aware. It was dealt with under the copyright statute, however, in the case of Bobbs-Merrill Co. v. Straus . [5]

In the Bobbs-Merrill case the Court held that the copyright was exhausted by the first sale, and:

[I]t was not the purpose of the law to grant the further right to qualify the title of future purchasers by means of the printed notice affixed to the book, and that to give such right would extend the statute beyond its fair meaning and secure privileges not intended to be covered by the Act of Congress. [6]

The Court recognized that "there are differences between the copyright statute and the patent statute, and the purpose to decide the question now before us was expressly disclaimed" in Bobbs–Merrill. Nonetheless, "it is apparent that, in the respect involved in the present inquiry, there is a strong similarity between and identity of purpose in the two statutes." Both statutes grant an exclusive right to "vend." There is no difference of importance in the respective legal rights to vend books and vend products:

So far as the use of the terms "vend" and "vending" is concerned, the protection intended to be secured is substantially identical. The sale of a patented article is not essentially different from the sale of a book. In each case, to vend is to part with the thing for a consideration. [7]

The patentee here insists that the purpose of notices fixing resale prices, specifically "keeping up prices and preventing competition"—is more essential to the protection of patented goods than of copyrighted books. The Court expressed doubt that this was so, but in any case it was more likely that "Congress had no intention to use the term 'vend' in one sense in the patent act and . . . in another in the copyright law." Congress intended to provide "[p}rotection in the exclusive right to sell . . . in both instances, and the terms used in the statutes are to all intents the same." [8]

Sanatogen, "crowned King of Tonics," according to this 1911 advertisement, was "a concentrated scientific food that constructively gives strength and vitality" 1911 adv't for Samtogen, King of Tonics.jpg
Sanatogen, "crowned King of Tonics," according to this 1911 advertisement, was "a concentrated scientific food that constructively gives strength and vitality"

The only significant difference is that patent law gives an exclusive right to use and copyright law does not. The Supreme Court decision involving a post-sale restraint on which the patentee places chief reliance here is Henry v. A.B. Dick Co. [9] But that decision was based on the exclusive use right:

[T]he restriction was sustained because of the right to use the machine granted in the patent statute, distinguishing in that respect the patent from the copyright act. In that case, a patented mimeograph had been sold which bore an inscription in the form of a notice that the machine was sold with the license restriction that it might only be used with stencil, ink, and other supplies made by the A. B. Dick Company, the owners of the patent. The alleged infringer sold to the purchaser of the mimeograph a can of ink suitable for use with machine, with full knowledge of the restriction, and with the expectation that the ink sold would be used in connection with the machine. [10]

Here, the patentee has argued "that the notice in this case deals with the use of the invention, because the notice states that the package is licensed 'for sale and use at a price not less than $1,' [and] that a purchase is an acceptance of the conditions. . ." But, the Court insisted:

[I]t is a perversion of terms to call the transaction in any sense a license to use the invention. The jobber from whom the appellee [O'Donnell] purchased had previously bought, at a price which must be deemed to have been satisfactory, the packages of Sanatogen afterwards sold to the appellee. The patentee had no interest in the proceeds of the subsequent sales, no right to any royalty thereon, or to participation in the profits thereof. The packages were sold with as full and complete title as any article could have when sold in the open market, excepting only the attempt to limit the sale or use when sold for not less than $1. In other words, the title transferred was full and complete, with an attempt to reserve the right to fix the price at which subsequent sales could be made. . . There was no transfer of a limited right to use this invention, and to call the sale a license to use is a mere play upon words. [11]

As in Bobbs-Merrill Co v. Straus , [12] with copyright, the Court ruled, restrictions could not be extended beyond the terms of the statute, which grants an exclusive right to vend but grants no "privilege to keep up prices and prevent competition by notices restricting the price at which the article may be resold." When the right to vend is exercised, patent rights are exhausted:

This being so, the case is brought within that line of cases in which this Court, from the beginning, has held that a patentee who has parted with a patented machine by passing title to a purchaser has placed the article beyond the limits of the monopoly secured by the patent act. [As in] Adams v. Burke , . . . in the essential nature of things, when the patentee, or the person having his rights, sells a machine or instrument whose sole value is in its use, he receives the consideration for its use and he parts with the right to restrict that use. The article, in the language of the court, passes without the limit of the monopoly. [13]

Commentary

● A contemporary Note in the Michigan Law Review said the case "was of vital importance to a large number of manufacturers," as was "evidenced by the various ingenious methods and devices which have since been adopted by numerous manufacturers to avoid the operation and application of the principles set forth in the decision," such as leasing and agency. The writer was surprised that "The tendency of the Supreme Court seems to be to take the view that the monopoly enjoyed by the patentee was not meant by Congress to be without limitation, and consequently to make it practically impossible for the patentee to control the retail price."

The writer maintains: "This decision by the Supreme Court was unquestionably a very great surprise to many, as it is not only directly in conflict with an almost unbroken line of decisions of the inferior federal courts," beginning with the Button-Fastener case, and "it is also nearly impossible to reconcile this decision" with Henry v. A. B. Dick Co. As for the Dick case, the writer continues, "It was generally thought that in the Dick case the Supreme Court had expressly committed itself to the doctrine that the patentee could require the user to comply with any conditions which he might choose to impose." He considers the distinction drawn with that case to be flimsy and not "clear, sound, or convincing." [14]

● A contemporary Note in the California Law Review also observed that in light of the A.B. Dick decision it was natural "that some slight surprise should be occasioned by the decision of the Supreme Court in the so-called Sanatogen case which holds that a patentee is without right to make or enforce a resale price stipulation." More accurately than the Michigan note, this note attributed the see-sawing in recent years to the changes in the personnel of a closely divided Court and successive replacements by new Roosevelt, Taft, and Wilson appointees:

It is of decided interest to note that the four justices who constituted the majority of the court in the Dick case, dissented from the decision of the Sanatogen case. Of the five justices who formed the majority in the latter decision, three had vigorously dissented in Henry v. Dick Company; the other two justices took no part in the determination of the earlier case. Whether there be a valid ground of distinction between the two cases or not, the results reached would seem to be best accounted for by the difference in the personnel of the court. The law on this and other similar questions in regard to a patentee's rights is apparently in a state of some uncertainty, and the presence or absence of certain justices would seem to be an important factor in the determination of any case which might arise in the future. [15]

● Granville Munson, in a 1917 article on post-sale restraints, found the A.B. Dick and Bauer cases irreconcilable: "It is submitted the Sanatogen case and the Dick case cannot both be upheld, although the court professes to distinguish the latter." He insisted that the exclusive right to "vend" must include the right to set terms and conditions on which the patented article will be vended, and not just the right to sell or not sell: "If the word, "vend," is to have any particular meaning in the patent law, it is submitted it must be taken to refer to the conditions which may be imposed on subsales." Munson therefore concludes that "the decision in Bauer & Cie v. O'Donnell should not be supported." [16]

● Charles Miller was critical of the Court's decision to suppress Bauer's resale price fixing:

The principal argument of those opposed to price maintenance among retailers, in legislative committees, and on the bench, is that after one has parted with title to an article, he should not be allowed further to control it. That idea seems to underlie the recent enunciations of the Supreme Court . . . The fallacy in this argument is that the manufacturer's interest in his product does not end with the transfer of title to the dealer, but follows the article into the hands of the ultimate consumer or user. His business life is dependent upon the public's being able to buy his article everywhere at a uniform price, and always of the same quality. Cut price sales will speedily and surely decrease the sale of his product; and if he is able to survive the loss of business, the manufacturer will be forced to reduce the quality of his article. One dealer advertising a so-called "cut price" sale invariably causes other dealers to cut below him in retaliation, with the result that all dealers in the community are forced to sell the particular article at a price which yields no profit. It hardly need be said they will not long continue to handle an article at a loss; so the market for the article is killed in that community, not because the people want the "just-as-good" substitute, nor because the quality of the article has been lowered, nor because the standard price is exorbitant, but because a business parasite used the good name of a popular article to deceive the. public into believing he sold everything below cost. [17]

He added:

The price cutter is not a philanthropist, lie is a robber, stealing the advertising and filching the good will of another's product; and like all thieves he does not share his booty with the public. "I cannot believe", said Mr. Justice Holmes in his strong dissent in the Dr. Miles Case, "that in the long run the public will profit by this court permitting knaves to cut reasonable prices for some ulterior purpose of their own, and thus to impair, if not destroy, the production and sale of articles which it is assumed to be desirable that the public should be able to get." [18]

See also

Related Research Articles

Bobbs-Merrill Co. v. Straus, 210 U.S. 339 (1908), was a United States Supreme Court decision concerning the scope of rights accorded owners of a copyright versus owners of a particular copy of a copyrighted work. This was a case of first impression concerning whether the copyright laws permit an owner to control a purchaser's subsequent sale of a copyrighted work. The court stated the issue as:

Does the sole right to vend secure to the owner of the copyright the right, after a sale of the book to a purchaser, to restrict future sales of the book at retail, to the right to sell it at a certain price per copy, because of a notice in the book that a sale at a different price will be treated as an infringement, which notice has been brought home to one undertaking to sell for less than the named sum?

The first-sale doctrine is an American legal concept that limits the rights of an intellectual property owner to control resale of products embodying its intellectual property. The doctrine enables the distribution chain of copyrighted products, library lending, giving, video rentals and secondary markets for copyrighted works. In trademark law, this same doctrine enables reselling of trademarked products after the trademark holder puts the products on the market. In the case of patented products, the doctrine allows resale of patented products without any control from the patent holder. The first sale doctrine does not apply to patented processes, which are instead governed by the patent exhaustion doctrine.

In United States patent law, patent misuse is a patent holder's use of a patent to restrain trade beyond enforcing the exclusive rights that a lawfully obtained patent provides. If a court finds that a patent holder committed patent misuse, the court may rule that the patent holder has lost the right to enforce the patent. Patent misuse that restrains economic competition substantially can also violate United States antitrust law.

The exhaustion doctrine, also referred to as the first sale doctrine, is a U.S. common law patent doctrine that limits the extent to which patent holders can control an individual article of a patented product after a so-called authorized sale. Under the doctrine, once an authorized sale of a patented article occurs, the patent holder's exclusive rights to control the use and sale of that article are said to be "exhausted," and the purchaser is free to use or resell that article without further restraint from patent law. However, under the repair and reconstruction doctrine, the patent owner retains the right to exclude purchasers of the articles from making the patented invention anew, unless it is specifically authorized by the patentee to do so.

General Talking Pictures Corp. v. Western Electric Co., 304 U.S. 175 (1938), was a case that the Supreme Court of the United States decided in 1938. The decision upheld so-called field-of-use limitations in patent licenses: it held that the limitations were enforceable in a patent infringement suit in federal court against the licensee and those acting in concert with it—for example, a customer that knowingly buys a patented product from the licensee that is outside the scope of the license.

<i>Mallinckrodt, Inc. v. Medipart, Inc.</i>

Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, is a decision of the United States Court of Appeals for the Federal Circuit, in which the court appeared to overrule or drastically limit many years of U.S. Supreme Court precedent affirming the patent exhaustion doctrine, for example in Bauer & Cie. v. O'Donnell.

Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), is a case decided by the United States Supreme Court in which the Court reaffirmed the validity of the patent exhaustion doctrine. The decision made uncertain the continuing precedential value of a line of decisions in the Federal Circuit that had sought to limit Supreme Court exhaustion doctrine decisions to their facts and to require a so-called "rule of reason" analysis of all post-sale restrictions other than tie-ins and price fixes. In the course of restating the patent exhaustion doctrine, the Court held that it is triggered by, among other things, an authorized sale of a component when the only reasonable and intended use of the component is to engage the patent and the component substantially embodies the patented invention by embodying its essential features. The Court also overturned, in passing, that the exhaustion doctrine was limited to product claims and did not apply to method claims.

United States v. Univis Lens Co., 316 U.S. 241 (1942), is a decision of the United States Supreme Court explaining the exhaustion doctrine and applying it to find an antitrust violation because Univis's ownership of patents did not exclude its restrictive practices from the antitrust laws. The Univis case stands for the proposition that when an article sold by a patent holder or one whom it has authorized to sell it embodies the essential features of a patented invention, the effect of the sale is to terminate any right of the patent holder under patent law to control the purchaser's further disposition or use of the article itself and of articles into which it is incorporated as a component or precursor.

United States v. General Electric Co., 272 U.S. 476 (1926), is a decision of the United States Supreme Court holding that a patentee who has granted a single license to a competitor to manufacture the patented product may lawfully fix the price at which the licensee may sell the product.

A post-sale restraint, also termed a post-sale restriction, as those terms are used in United States patent law and antitrust law, is a limitation that operates after a sale of goods to a purchaser has occurred and purports to restrain, restrict, or limit the scope of the buyer's freedom to utilize, resell, or otherwise dispose of or take action regarding the sold goods. Such restraints have also been termed "equitable servitudes on chattels".

Standard Sanitary Mfg. Co. v. United States, 226 U.S. 20 (1912), also known as the Bathtub Trust case, was a United States Supreme Court decision in which the Court held unanimously that ownership of patent rights does not immunize the owner from the antitrust laws prohibiting combinations in unreasonable restraint of trade. The Court famously said that the Sherman Act "is its own measure of right and wrong, of what it permits or forbids, and the judgment of the courts cannot be set up against it in a supposed accommodation of its policy with the good intention of parties, and, it may be, of some good results." A 1917 commentary said, "This decision has become the leading case on the subject of the relation of the patent law and Sherman law to each other."

Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502 (1917), is United States Supreme Court decision that is notable as an early example of the patent misuse doctrine. It held that, because a patent grant is limited to the invention described in the claims of the patent, the patent law does not empower the patent owner, by notices attached to the patented article, to extend the scope of the patent monopoly by restricting the use of the patented article to materials necessary for their operation but forming no part of the patented invention, or to place downstream restrictions on the articles making them subject to conditions as to use. The decision overruled The Button-Fastener Case, and Henry v. A.B. Dick Co., which had held such restrictive notices effective and enforceable.

Ethyl Gasoline Corp. v. United States, 309 U.S. 436 (1940), was a decision of the United States Supreme Court that limited the doctrine of the Court's 1938 decision in General Talking Pictures Corp. v. Western Electric Co. Beginning with the 1926 decision in United States v. General Electric Co., the Supreme Court made a sharp distinction between (i) post-sale restraints that a patentee imposed on purchasers of a patented product and (ii) restrictions (limitations) that a patentee imposed on a licensee to manufacture a patented product: the former being illegal and unenforceable under the exhaustion doctrine while the latter were generally permissible under a lenient "rule of reason." Thus, under the General Talking Pictures doctrine, a patent holder may permissibly license others to manufacture and then sell patented products in only a specified field (market), such as only a particular type of product made under the patent or only a particular category of customer for the patented product. The Ethyl decision held, however, that a patent licensing and distribution program based on both the sale of a patented product and licenses to manufacture a related product was subject to ordinary testing under the antitrust laws, and accordingly was illegal when its effect was to "regiment" an entire industry.

Henry v. A.B. Dick Co., 224 U.S. 1 (1912), was a 1912 decision of the United States Supreme Court that upheld patent licensing restrictions such as tie-ins on the basis of the so-called inherency doctrine—the theory that it was the inherent right of a patent owner, because he could lawfully refuse to license his patent at all, to exercise the "lesser" right to license it on any terms and conditions he chose. In 1917, the Supreme Court overruled the A.B. Dick case in Motion Picture Patents Co. v. Universal Film Mfg. Co.,

<i>Button-Fastener case</i>

The Button-Fastener Case, Heaton-Peninsular Button-Fastener Co. v. Eureka Specialty Co., also known as the Peninsular Button-Fastener Case, was for a time a highly influential decision of the United States Court of Appeals for the Sixth Circuit. Many courts of appeals, and the United States Supreme Court in the A.B. Dick case adopted its "inherency doctrine"—"the argument that, since the patentee may withhold his patent altogether from public use, he must logically and necessarily be permitted to impose any conditions which he chooses upon any use which he may allow of it." In 1917, however, the Supreme Court expressly overruled the Button-Fastener Case and the A.B. Dick case, in the Motion Picture Patents case.

Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. ___ (2017), is a decision of the Supreme Court of the United States on the exhaustion doctrine in patent law in which the Court held that after the sale of a patented item, the patent holder cannot sue for patent infringement relating to further use of that item, even when in violation of a contract with a customer or imported from outside the United States. The case concerned a patent infringement lawsuit brought by Lexmark against Impression Products, Inc., which bought used ink cartridges, refilled them, replaced a microchip on the cartridge to circumvent a digital rights management scheme, and then resold them. Lexmark argued that as they own several patents related to the ink cartridges, Impression Products was violating their patent rights. The U.S. Supreme Court, reversing a 2016 decision of the Federal Circuit, held that the exhaustion doctrine prevented Lexmark's patent infringement lawsuit, although Lexmark could enforce restrictions on use or resale of its contracts with direct purchasers under regular contract law. Besides printer and ink manufacturers, the decision of the case could affect the markets of high tech consumer goods and prescription drugs.

Leitch Manufacturing Co. v. Barber Co., 302 U.S. 458 (1938), is a 1938 decision of the United States Supreme Court extending the tie-in patent misuse doctrine to cases in which the patentee does not use an explicit tie-in license but instead relies on grants of implied licenses to only those who buy a necessary supply from it.

<i>United States v. Motion Picture Patents Co.</i>

United States v. Motion Picture Patents Co. , 225 F. 800, was a civil antitrust prosecution overlapping to some extent with the issues in the decision in the Supreme Court's Motion Picture Patents case. After the trial court found that the defendants violated §§ 1 and 2 of the Sherman Act by establishing control over "trade in films, cameras, projecting machines, and other accessories of the motion picture business," by their patent licensing practices and other conduct, they appealed to the Supreme Court. After the Supreme Court's 1917 decision in Motion Picture Patents Co. v. Universal Film Manufacturing Co., however, the parties dismissed the appeal by stipulation in 1918 that the decision had made the defendants' appeal futile.

<i>United States v. Vehicular Parking Ltd.</i>

United States v. Vehicular Parking Ltd. is a patent–antitrust case in which the United States Government eroded the doctrine of United States v. General Electric Co. permitting patentees to fix licensee prices, but failed to persuade the court to decree royalty-free licensing as a remedy.

United States v. Line Material Co., 333 U.S. 287 (1948), is a decision of the United States Supreme Court limiting the doctrine of the 1926 General Electric decision, excusing price fixing in patent license agreements. The Line Material Court held that cross-licenses between two manufacturer competitors, providing for fixing the prices of the licensed products and providing that one of the manufacturers would license other manufacturers under the patents of each manufacturer, subject to similar price fixing, violated Sherman Act § 1. The Court further held that the licensees who, with knowledge of such arrangements, entered into the price-fixing licenses thereby became party to a hub-and-spoke conspiracy in violation of Sherman Act § 1.

References

The citations in this article are written in Bluebook style. Please see the talk page for more information.

  1. See advertisement at right, N.Y. Daily Tribune, p.2 (June 23, 1911). A January 1913 article in Good Housekeeping stated that Sanatogen "was representative of the class of advertised tonics which make exaggerated claims and charge a high price." It added that $1 worth of Sanatogen was equivalent to 6¢ worth of milk and 1¢ worth of wheat flour.
  2. 229 U.S. at 8.
  3. 229 U.S. at 8–9.
  4. 229 U.S. at 11.
  5. 229 U.S. at 12.
  6. 229 U.S. at 12.
  7. 229 U.S. at 13.
  8. 229 U.S. at 13.
  9. 224 U.S. 1 (1912).
  10. 229 U.S. at 14 (emphasis added).
  11. 229 U.S. at 16.
  12. 210 U.S. 339 (1908).
  13. 229 U.S. at 17–18.
  14. Note, The Right of the Patentee to Control the Resale Price, 12 Mich. L. Rev. 394 (1914).
  15. Note, Right of Patentee to Restrict Sale and Use of Patented Article, 2 Cal. L. Rev. 80, 81 (1913).
  16. F. Granville Munson, Control of Patented and Copyrighted Articles after Sale, 26 Yale L.J. 270, - (1917).
  17. Charles L. Miller, The Maintenance of Uniform Resale Prices, 63 U. Pa. L. Rev. 22, 30 (1914).
  18. Id. at 33.